Global Small Molecule Active Pharmaceutical Ingredient (API) Market Segmentation, By Type (Synthetic/Chemical API, Biological API), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology), Manufacturing Method (In-House, Contract), Application (Clinical, Commercial) – Industry Trends and Forecast to 2031.
Small Molecule Active Pharmaceutical Ingredient (API) Market Analysis
Small molecules active pharmaceutical ingredient (API) are typically made up of 20–100 atoms and are well defined, purified, and studied easily. Small molecules are widely utilized to treat several illnesses and ailments and have various mechanisms of action. They can be efficient allosteric modifiers and enzyme inhibitors due to their usual physicochemical characteristics and tiny size. They can target intracellular receptors or extracellular proteins in the central nervous system, nucleus, and cytoplasm.
Small Molecule Active Pharmaceutical Ingredient (API) Market Size
Global small molecule active pharmaceutical ingredient (API) market size was valued at USD 195.31 million in 2023 and is projected to reach USD 300.88 million by 2031, with a CAGR of 5.55% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Small Molecule Active Pharmaceutical Ingredient (API) Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Albemarle Corporation (U.S.), Allergan (Ireland), Aurobindo Pharma (India), Cambrex Corporation (U.S.), Dr. Reddy’s Laboratories Ltd (India), GSk plc (U.K.), Lonza (Switzerland), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Siegfried Holding AG (Switzerland), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd. (Israel), Johnson Matthey (U.K.), Gilead Sciences, Inc. (U.S.), BASF SE (Germany)
|
|
Market Opportunities
|
|
Small Molecule Active Pharmaceutical Ingredient (API) Market Definition
A low molecular weight organic compound with a size of around 1 nm is referred to as a tiny molecule active pharmaceutical ingredient (API), which helps to control the biological process. Orally administered tiny molecules can be any type, and the body will most likely take them in. Due to its tiny size and ability to quickly diffuse to the intracellular site of action, it has these qualities.
Small Molecule Active Pharmaceutical Ingredient (API) Market Dynamics
Drivers
- Increasing prevalence of diseases
The main drivers of the small molecule API market are the rising prevalence of diseases including cancer, cardiovascular disease, and infections, the creation of businesses producing small molecule APIs, and the patent expirations of the best-selling medications. The expansion of the small molecule active pharmaceutical ingredient (API) market is accelerated by an increase in corporate partnerships, simple access to medicine in emerging economies, and rising consumer awareness of the advantages of small molecule API.
- Technological developments in manufacturing sector
The market for small molecule APIs is impacted by the rising rate of generic pharmaceuticals and increased production of small molecule APIs due to technical advancements in the manufacturing sector. Additionally, the market for small molecule API is favourably impacted by the growing geriatric population, increase in disease and treatment awareness among people, research and development activities, improved healthcare infrastructure, and rise in healthcare spending.
- Increase in outsourcing trend
The market's expanding need for small molecule medications and the rising outsourcing trend are two of the key drivers. The arrival of new companies that fuel the demand for raw materials like API for the low-cost synthesis of pharmaceuticals is made possible by the patent expiry of dominant compounds, which is further fuelling growth.
Opportunities
- Increase in the small scale production
A paradigm shift in the sector is anticipated to be triggered by the increased use of breakthrough technologies and the advent of specialised pharmaceuticals. Instead, a rise in small scale production is anticipated. Additionally, as more items are released and manufactured, adaptable production facilities and reliable procedures are being built to satisfy shifting demands.
Restraints/Challenges
On the other hand, it is anticipated that the implementation of strict regulatory requirements and the economic downturn will impede the growth of the small molecule API industry. The small molecule API industry is anticipated to face challenges from new entrants' mounting financial problems between 2024 and 2031.
This small molecule active pharmaceutical ingredient (API) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the small molecule active pharmaceutical ingredient (API) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Small Molecule Active Pharmaceutical Ingredient (API) Market
The COVID-19 epidemic has helped the market flourish by motivating participants to spread their businesses geographically to prevent shortages. In order to tackle the illness, research into small molecule drugs like Molnupiravir is being accelerated via COVID-19. It is also being researched whether small molecule medications already on the market can be used to treat SARS-CoV-2 infection.
Small Molecule Active Pharmaceutical Ingredient (API) Market Scope
The small molecule active pharmaceutical ingredient (API) market is segmented on the basis of type, therapeutic type, manufacturing method, application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Synthetic/Chemical API
- Biological API
Therapeutic Type
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Dermatology
- Urology
Manufacturing Method
- In-House
- Contract
Application
- Clinical
- Commercial
Small Molecule Active Pharmaceutical Ingredient (API) Market Regional Analysis
The small molecule active pharmaceutical ingredient (API) market is analysed and market size insights and trends are provided by country, type, therapeutic type, manufacturing method, application as referenced above.
The countries covered in the small molecule active pharmaceutical ingredient (API) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the small molecule active pharmaceutical ingredient (API) market due to the active pharmaceutical ingredient market in the region which is being alternated as large pharmaceutical organizations dedicate assets increasingly to the advancement of biologic services.
Asia-Pacific is expected to show significant amount of growth in the small molecule active pharmaceutical ingredient (API) market due to the actions that have been taken to encouraging generic drug growth with costing and repayment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Small Molecule Active Pharmaceutical Ingredient (API) Market Share
The small molecule active pharmaceutical ingredient (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to small molecule active pharmaceutical ingredient (API) market.
Small Molecule Active Pharmaceutical Ingredient (API) Market Leaders Operating in the Market Are:
- Albemarle Corporation (U.S.)
- Allergan (Ireland)
- Aurobindo Pharma (India)
- Cambrex Corporation (U.S.)
- Dr. Reddy’s Laboratories Ltd (India)
- GSk plc (U.K.)
- Lonza (Switzerland)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Siegfried Holding AG (Switzerland)
- Sun Pharmaceutical Industries Ltd (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson Matthey (U.K.)
- Gilead Sciences, Inc. (U.S.)
- BASF SE (Germany)
Latest Developments in Small Molecule Active Pharmaceutical Ingredient (API) Market
- In January 2020, Sandoz's position in the global market for generic drugs and off-patent medications was boosted by this acquisition
SKU-